Unchained Labs Unveils LEA 9 Software Making Workflows Easy
Image credit: Unchained Labs
Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, has now released its LEA 9 software, making Freeslate and Junior automation systems way more accessible.
LEA, short for Laboratory Execution and Analysis Software, controls Freeslate and Junior systems, executes biologics and chemistry workflow designs, integrates third-party tools, and keeps all the data in one place.
LEA 9 adds a step-by-step workflow tool called Design Creator into the mix. There’s no coding, scripting or messing around with protocols. Scientists just drag and drop their workflow steps into place and they’re good to go. Design Creator also double checks each step to make sure it’s doable, so newbie users don’t have to worry about screwing things up.
“Freeslate and Junior already help researchers wipe out major hassles from their toughest workflows,” said Taegen Clary, VP of Marketing at Unchained Labs. “Automation can be insanely complicated, and really nerve wracking for casual users. LEA 9 makes lab automation totally easy and approachable for anyone.”
This article has been republished from materials provided by Unchained Labs. Note: material may have been edited for length and content. For further information, please contact the cited source.
Diabetic Ketoacidosis Assay Collaboration Between Ortho Clinical Diagnostics and EKF DiagnosticsNews
EKF’s Beta-Hydroxybutyrate LiquiColor® Assay for detection of predominant ketone body now available on Ortho’s VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System.READ MORE
Fabric Genomics Partners to Improve Pediatric CareNews
Partnerships with Genomics England, Rady Children's Institute for Genomic Medicine, and The Utah Genome Project demonstrate diagnostic utility of Fabric Genomics' algorithm-based genome analysis.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE